产品
编 号：F218500
分子式：C26H26ClN5O
分子量：459.97
分子式：C26H26ClN5O
分子量：459.97
产品类型
规格
价格
是否有货
结构图
CAS No: 1802637-39-3
产品详情
生物活性：
BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.
体内研究：
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely.Animal Model:MRL/lpr mice.
Dosage:1 mg/kg.
Administration:Subcutaneous injection daily from 8 to 14 weeks of age.
Result:Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs.
BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.
体内研究：
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely.Animal Model:MRL/lpr mice.
Dosage:1 mg/kg.
Administration:Subcutaneous injection daily from 8 to 14 weeks of age.
Result:Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备